All News

heart in a puzzle

What would it take for JAKs to ROCK the boat?

d David Liew, FRACP

JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might have a cardioprotective effect. It is therefore worth excitement that we have a therapeutic option to follow which does just that. At EULAR 2025, we have seen phase 2 results for CPL’116, and a simultaneous publication in The Lancet Rheumatology.

Read Article
light bulb idea

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

During EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). This is an anti-neonatal Fc receptor (FcRn) mAb that reduces circulating IgG, including autoantibodies, by selectively blocking the interaction of IgG with FcRn. A year on at EULAR 2025, data from Phase 2 RCT of efgartigimod, an FcRn-inhibitor were presented in autoantibodies positive, moderate to severe active SjD. In addition to SjD, data from Phase 2 RCT of efgartigimod in inflammatory myopathies was presented.

Read Article
puzzle.RA_.jpg

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials

d Mrinalini Dey, MD

Advances in the treatment of rheumatoid arthritis, particularly the treat-to-target strategy and the introduction of effective DMARDs, have improved the management of inflammation in RA. However, improved inflammatory markers do not always translate into a resolution of patients’ symptoms or improvements in functional capacity. A recent pooled analysis from the CareRA and CareRA2020 randomized controlled trials shed new light on this dissociation between biological disease control and patient-reported outcomes.

Read Article
Pregnancy outcomes in autoinflammatory disease To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual https://t.co/oQ7A2bnDmO
Dr. John Cush RheumNow ( View Tweet)
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk - Chikungunya - Dengue - Zika - West-Nile Virus @RheumNow #EULAR2025 @bella_mehta https://t.co/CCOYqTjaXE
Dr. John Cush RheumNow ( View Tweet)
From Domains to Decisions: Personalizing PsA Care with Data At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; https://t.co/tzgE7U4eSj
Dr. John Cush RheumNow ( View Tweet)
New ideas in gout management Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. https://t.co/C8G39JzP9Y https://t.co/NAClL0JLGX

Links:

Dr. John Cush RheumNow ( View Tweet)
Reviewing Three Osteoarthritis Studies Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/0qub4ITnxa https://t.co/uguzPSnvCR

Links:

Dr. John Cush RheumNow ( View Tweet)
Which CAR T Cell is Mighty? Dr. Yuz Yusof talks with Dr. Chris Wincup about CAR T data being presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/MkRoqlvdub https://t.co/R0dtllmo7Q

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – Day 3 Report Highlights from Day 3 included presentations on imaging in vasculitis, a debate on treating high-risk pre-clinical RA, and EULAR Recommendations on ILD treatment, physical activity for arthritis, the EULAR disease activity score for antiphospholipid https://t.co/FAaj443wPX
Dr. John Cush RheumNow ( View Tweet)
Imaging and Early Detection in Psoriatic Arthritis At EULAR 2025, there have been new developments in imaging in PsA. Two key poster presentations (POS0104 and OP0179) provide important insights into the role of imaging in the management and early detection of psoriatic https://t.co/41fgXj5WnN
Dr. John Cush RheumNow ( View Tweet)
Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/35cWYRehdd
Dr. John Cush RheumNow ( View Tweet)
Predictors and Outcomes in Systemic Sclerosis The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/9dJn1qMQfy
Dr. John Cush RheumNow ( View Tweet)
Multinational metanalyses of 24 studies & 1,173,410 participants shows alcohol increases risk of hyperuricemia (OR 1.51) and gout (OR 1.81) - more so in males > females. Little effect of age, country, study type, type of alcohol, Dx criteria in regression analyses. https://t.co/NSYTppcKzV
Dr. John Cush RheumNow ( View Tweet)
Several studies have shown predictive value to monocyte counts in RA responses. UK study of 246 #RA pts showed pretreatment absolute monocyte count [ORadj 9.56; 1.61-59.86, p = 0.01) predicted bDMARD nonresponse @ 6 mos. Replicates other reports! https://t.co/GqGj8R0wq1 https://t.co/HJ7wFBoxGE

Links:

Dr. John Cush RheumNow ( View Tweet)
Steroids, Not JAKi, Are the Real Infection Risk Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain. https://t.co/rLpyo1UNjd https://t.co/bDfdLTEM1N

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Daily Recap: Day 1 and 2 LIVE Daily Recap Day 1 & 2 – EULAR 2025 Coverage brings you the latest updates from EULAR 2025. Join Dr. Jack Cush, Dr. Mrinalini Dey, Dr. Antoni Chan, and Dr. Nelly Ziade as they discuss the biggest breakthroughs, standout sessions, and expert https://t.co/vkTo2MchsC
Dr. John Cush RheumNow ( View Tweet)
Using Combination csDMARDs in PsA Dr. Eric Ruderman shares his insights on abstracts OP0093, OP0106, and POS0106, which discuss the effectiveness of combination csDMARD therapy, long-term outcomes of methotrexate and leflunomide, and a real-world treat-to-target strategy in https://t.co/Pv4YEyYShm
Dr. John Cush RheumNow ( View Tweet)
Social Determinants of Health in SLE SDH, such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, https://t.co/Xf2bR7ap5m
Dr. John Cush RheumNow ( View Tweet)
Jokes Aside: The Impact of Laughter in RA Dr. Aurelie Najm reports on POS0685, 'The Impact of Social Frailty and Physical Function on Laughter Frequency in Rheumatoid Arthritis Patients from a Multicenter Observational Study (T-FLAG)', presented at EULAR 2025 in Barcelona, https://t.co/z3tvqQmH96
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×